ArticleNorth American journal of medical sciences2012
Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases.
Article in North American journal of medical sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 107 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
107 citing papers in PubMed, 1 synthesis or guideline pooled it, 207 citations in OpenAlex.
- Association between serum paraoxonase 1 activity and its polymorphisms with multiple sclerosis: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Pooled it
- Genetic Variability of Antioxidative Mechanisms and Cardiotoxicity after Adjuvant Radiotherapy in HER2-Positive Breast Cancer Patients.Disease markers · 2020Trial
- Trial
- Conjugated linoleic acid improves glycemic response, lipid profile, and oxidative stress in obese patients with non-alcoholic fatty liver disease: a randomized controlled clinical trial.Croatian medical journal · 2016Trial
- Reduced Serum PON1 Lactonase Activity Is Associated with Mild Cognitive Impairment and Mixed Dementia.Antioxidants (Basel, Switzerland) · 2026Article
- A Multilevel Redox-Based Prognostic Model for Asthma Severity: From Genotype to Serum Biomarkers.Biomedicines · 2026Review
- Single-cell fixed RNA profiling uncovers SEMA4D and LMCD1 as therapeutic targets in a liver fibrosis model.JHEP reports : innovation in hepatology · 2026Article
- Serum cystatin C as a biomarker in non-Hodgkin lymphoma and its relationship with paraoxonase 1 activity.Journal of medical biochemistry · 2026Article
- The effect of estradiol and selective estrogen receptor modulators on lipid profile in the ovariectomized rat model.Research in pharmaceutical sciences · 2026Article
- Changes in Apolipoprotein A1-Associated Proteomic Composition After Pioglitazone Treatment Versus Weight Loss.International journal of molecular sciences · 2025Article
- Periodontal Implications of Porphyromonas gingivalis-Derived Metabolites in Host Antioxidant and Anti-Inflammatory Mechanisms: A Computational Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Effects of thymoquinone and the curcumin analog EF-24 on the activity of the enzyme paraoxonase-1 in human glioblastoma cells U87MG.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Loss of interferon regulatory factor-1 prevents lung fibrosis by upregulation of pon1 expression.Respiratory research · 2024Article
- PON1 and PON3 in Alzheimer's Disease: Similar Functions but Different Roles.Antioxidants (Basel, Switzerland) · 2024Article
- High-Density Lipoprotein-Associated Paraoxonase-1 (PON-1) and Scavenger Receptor Class B Type 1 (SRB-1) in Coronary Artery Disease: Correlation with Disease Severity.Journal of clinical medicine · 2024Article
- A comprehensive insight from molecular docking and dynamics with clinical investigation on the impact of direct oral anticoagulants on atheroprotective protein in atrial fibrillation.BMC pharmacology & toxicology · 2024Article
- Differences in HDL Remodeling during Healthy Pregnancy and Pregnancy with Cardiometabolic Complications.Antioxidants (Basel, Switzerland) · 2024Article
- Diacerein mitigates endocrine and cardio-metabolic disruptions in experimental PCOS mice model by modulating AdipoR1/ PON 1.BMC endocrine disorders · 2024Article
- Ethnic Disparities in the Risk Factors, Morbidity, and Mortality of Cardiovascular Disease in People With Diabetes.Journal of the Endocrine Society · 2024Review
- Role of Oxidative Stress in Tuberculosis Meningitis Infection in Diabetics.Biomedicines · 2023Review
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraoxonase 1 (PON1) is a hydrolytic enzyme with wide range of substrates, and capability to protect against lipid oxidation. Despite of the large number of compounds that can be hydrolyzed by paraoxonase, the biologically relevant substrates are still not clearly determined. There is a massive in vitro and in vivo data to demonstrate the beneficial effects of PON1 in several atherosclerosis-related processes. The enzyme is primarily expressed in liver; however, it is also localized in other tissues. PON1 attracted significant interest as a protein that is responsible for the most of antioxidant properties of high-density lipoprotein (HDL). Several bioactive molecules such as dietary polyphenols, aspirin and its hydrolysis product salicylate, are known to stimulate PON1 transcription activation in mouse liver and HepG2 cell line. Studies on the activity, function, and genetic makeup have revealed a protective role of PON1. Some striking data were obtained in PON1 gene knockout and PON1 transgenic mouse models and in human studies. The goal of this review is to assess the current understanding of PON1 expression, enzymatic and antioxidant activity, and its atheroprotective effects. Results from in vivo and in vitro basic studies; and from human studies on the association of PON1 with coronary artery disease (CAD) and ischemic stroke will be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.